This article is more than 5 years old. Information may no longer be current.

Sanofi-aventis partners with the Vision Institute for eye disease research

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

PARIS — Sanofi-aventis has signed a cooperation agreement with the Vision Institute to research the diagnosis, prevention and treatment of ocular diseases, the company announced in a press release.

Under the 3-year agreement, Fovea Pharmaceuticals, sanofi-aventis' ophthalmology division, will have priority access to the Vision Institute's technological platforms to research and develop new ophthalmic therapies.

Sanofi-aventis will have exclusive and worldwide rights to results of the collaboration and will pay royalties to members of the Vision Institute in the event of commercialization.

"This collaboration will encourage the sharing of technical expertise and know-how with the objective to deliver innovative therapies for people with visual impairment and supports our ambition to build a global offer in ophthalmology for patients," Christopher A. Viehbacher, CEO of sanofi-aventis, said in the release.